Skip To Main Content
Alison Kanski on Muck Rack

Alison Kanski

Verified
Seattle
As seen in: Precision Oncology News, Scientific American, The Weather Channel, DNews, Grist, Campaign (UK), PR Week, RenewEconomy, Campaign (US), Climate Central, GenomeWeb and
Biopharma reporter, Precision Oncology News @PrecOncNews Previously: @MMMnews @PRWeek. Views are mine, but I never tweet.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alison

Contact Alison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enhertu Data in Frontline HER2-Mutant NSCLC Raises Question About How to Best Sequence Therapies

|
By Alison Kanski Verified
| GenomeWeb Verified
NEW YORK – Lung cancer patients with HER2 mutations lived longer without disease progression and more saw their tumors shrink with AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan) than they did with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) and chemotherapy in a Phase III trial.
Open in Who Shared Issue with article?

Amid Rasonque Excitement, Biomarker Testing Remains Important in Pancreatic Cancer Care

|
By Alison Kanski Verified
| Precision Medicine Online Verified
NEW YORK – While oncologists and pancreatic cancer patients are celebrating the US approval of Revolution Medicines' Rasonque (daraxonrasib), they are also awaiting more data on how well the drug works in those without RAS mutations and hopeful that this will usher in more next-generation pan-RAS inhibitors.
Open in Who Shared Issue with article?

It Takes More Than Insurance Coverage to Standardize NGS Testing in Practice, Study Shows

|
By Alison Kanski Verified
| 360Dx Verified
NEW YORK – An analysis of Medicare claims data over seven years found that uptake of next-generation sequencing in cancer was slower than expected after Medicare began covering testing. The research, published in JAMA Network Open in July, showed that use of NGS testing did increase over the seven-year period, but also that persistent access gaps remained when testing was performed for patients with certain tumor types even after broad, national Medicare coverage was established.
Open in Who Shared View Duplicates (2) Issue with article?
See all 445 licensed articles (1,036 Total)